Literature DB >> 32430285

Apolipoprotein(a), an enigmatic anti-angiogenic glycoprotein in human plasma: A curse or cure?

Vasantha Kalaivani1, Abdul Jaleel2.   

Abstract

Angiogenesis is a finely co-ordinated, multi-step developmental process of the new vascular structure. Even though angiogenesis is regularly occurring in physiological events such as embryogenesis, in adults, it is restricted to specific tissue sites where rapid cell-turnover and membrane synthesis occurs. Both excessive and insufficient angiogenesis lead to vascular disorders such as cancer, ocular diseases, diabetic retinopathy, atherosclerosis, intra-uterine growth restriction, ischemic heart disease, stroke etc. Occurrence of altered lipid profile and vascular lipid deposition along with vascular disorders is a hallmark of impaired angiogenesis. Among lipoproteins, lipoprotein(a) needs special attention due to the presence of a multi-kringle protein subunit, apolipoprotein(a) [apo(a)], which is structurally homologous to many naturally occurring anti-angiogenic proteins such as plasminogen and angiostatin. Researchers have constructed different recombinant forms of apo(a) (rhLK68, rhLK8, RHACK2, KV-11, and AU-6) and successfully exploited its potential to inhibit unwanted angiogenesis during tumor metastasis and retinal neovascularization. Similar to naturally occurring anti-angiogenic proteins, apo(a) can directly interfere with angiogenic signaling pathways. Besides this, apo(a) can also exert its anti-angiogenic effect indirectly by inducing endothelial cell apoptosis, by inhibiting endothelial progenitor cell functions or by upregulating nuclear factors in endothelial cells via apo(a)-bound oxPLs. However, the impact of the anti-angiogenic potential of native apo(a) during physiological angiogenesis in embryos and wounded tissues is not yet explored. In this context, we review the studies so far done to demonstrate the anti-angiogenic activity of apo(a) and the recent developments in using apo(a) as a therapeutic agent to treat impaired angiogenesis during vascular disorders, with emphasis on the gaps in the literature.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-angiogenic therapy; Apo(a); Kringle; Lipoprotein(a); Vascular diseases

Mesh:

Substances:

Year:  2020        PMID: 32430285     DOI: 10.1016/j.phrs.2020.104858

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  3 in total

1.  The Relationship between Intracarotid Plaque Neovascularization and Lp (a) and Lp-PLA2 in Elderly Patients with Carotid Plaque Stenosis.

Authors:  Chang Sun; Na Xi; Zhijun Sun; Xinxin Zhang; Xiaowei Wang; Huiyang Cao; Xiaowei Jia
Journal:  Dis Markers       Date:  2022-04-21       Impact factor: 3.464

Review 2.  The known unknowns of apolipoprotein glycosylation in health and disease.

Authors:  Sabarinath Peruvemba Subramanian; Rebekah L Gundry
Journal:  iScience       Date:  2022-08-28

3.  The association of lipoprotein(a) and intraplaque neovascularization in patients with carotid stenosis: a retrospective study.

Authors:  Shuang Xia; Weida Qiu; Anping Cai; Bo Kong; Lan Xu; Zejia Wu; Liwen Li
Journal:  BMC Cardiovasc Disord       Date:  2021-06-09       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.